The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination； a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof； use of such combination for the treatment of proliferative disease； and a commercial package comprising such combination； said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).本發明涉及如下藥物組合，該藥物組合包含(a)結合程式性死亡1(PD-1)的至少一種抗體分子(例如，人源化抗體分子)，和(b)HDM2-p53相互作用抑制劑，所述組合用於同時、分開或順序給予，用於在增殖性疾病的治療中使用；涉及包含這種組合藥物組成物；涉及治療患有增殖性疾病的受試者之方法，該方法包括向有需要的受試者給予所述組合；涉及這種組合用於治療增殖性疾病的用途；以及涉及包含這種組合的商業包裝物；所述增殖性疾病為TP53野生型腫瘤，特別是TP53野生型腎細胞癌(RCC)或TP53野生型結腸直腸癌(CRC)。
